H eart failure (HF) is the most common cardiovascular disorder in clinical practice.
Mitophagy is a specific class of autophagy that cleans out dysfunctional mitochondria in the heart under normal physiological conditions, as well as in response to pathological stresses. Although accumulating evidence suggests that the dysregulation of mitophagy can induce cardiomyocyte death and HF, [5] [6] [7] the basic regulation mechanisms underlying organelle-specific mitophagy during pathological HF have not been well elucidated.
Currently, most studies have demonstrated that the mechanism of mitophagy in cardiomyocytes is mediated by the cytosolic E3 ubiquitin ligase, Parkin, 8 and the mitochondrial membrane kinase, PINK1 (PTEN-induced putative kinase 1). 9 PINK1 is selectively stabilized in mitochondria with diminished electrochemical potentials across their inner membranes and recruits Parkin to the mitochondria to activate its E3 ubiquitin ligase activity. The Parkin-mediated ubiquitination of mitochondrial outer membrane proteins is the signal for engulfment of the organelle by autophagosomes and subsequent transfer to degradative lysosomes; thereafter, the components are either recycled or eliminated. Previous studies have revealed that the stabilization of PINK1 on the depolarized mitochondrial membrane recruits Parkin to the mitochondria by phosphorylating MFN2 (mitofusin 2) 10 ; this process is accelerated after the autophosphorylation of PINK1. 11 The damaged mitochondria are sensed by the decrease in mitochondrial membrane potential (ΔΨm) and transduced to Parkin via the autophosphorylation of PINK1, thus highlighting the importance of PINK1 in regulating the PINK1-Parkin-mediated mitophagy pathway.
AMPK (AMP-activated protein kinase) is a cellular energy sensor and a metabolic master switch that plays a pivotal role in cell growth and survival, as well as in whole-body energy homeostasis. 12, 13 AMPK is a heterotrimeric complex composed of a catalytic α-subunit and 2 regulatory β-and γ-subunits. Each subunit exists in multiple isoforms encoded by separate genes (α1, α2, β1, β2, γ1, γ2, and γ3). AMPK is activated in response to stresses that deplete intracellular ATP, leading to a rise in the AMP/ATP ratio. Increased AMPK activity leads to the phosphorylation of an array of protein targets, resulting in enhanced ATP production and reduced energy expenditure. 14, 15 AMPK activity is markedly increased during cardiac stresses such as ischemia 16 and pathological cardiac hypertrophy, 17, 18 and the failure to activate AMPK under these conditions is associated with a poor outcome. Furthermore, AMPK-mediated general autophagy is essential for the ischemic response in the heart. 16 A recent study has shown that AMPK mediates mitochondrial fission in response to energy stress. 19 However, whether AMPK is involved in selective mitophagy or the maintenance of mitochondrial function via mitophagy during HF is currently unknown.
In this study, we used heart samples from HF patients and AMPKα2 genetically modified mouse models with transverse aortic constriction (TAC) to investigate the role of AMPKα2-mediated selective mitophagy during HF. We identified a serine residue (Ser495) in PINK1 that underwent phosphorylation after exposure to AMPKα2 on dissipation of the ΔΨm in cardiomyocytes. Our results show that this phosphorylation event was important for the efficient retrieval of Parkin to the mitochondria to increase the rate of mitophagy during HF. 
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Novelty and Significance
What Is Known?
• Mitochondrial dysfunction is a common cause of heart failure (HF).
• Activation of AMPK (5′-AMP-activated protein kinase) can prevent HF and increase general autophagy.
What New Information Does This Article Contribute?
• Isoform shift of the predominant AMPKα2 (AMP-activated protein kinase-α2) to the AMPKα1 was observed in the failing hearts from HF patients and in mice subjected to transverse aortic constriction.
• AMPKα2 regulates cardiac mitophagy during transverse aortic constriction-induced HF in mice.
• Genetic knockdown of AMPKα2, but not AMPKα1 by siRNA, suppressed phenylephrine-induced mitophagy.
• AMPKα2 specifically interacted with and phosphorylated PINK1 (PTENinduced putative kinase 1) at Ser495 after phenylephrine stimulation, and in turn, enhanced the role of the PINK1-Parkin-SQSTM1 (sequestosome 1) pathway involved in cardiac mitophagy.
This study investigated the roles of AMPKα1 and AMPKα2 in HF, specifically in terms of mitophagy. We found that HF is accompanied by an isoform switch from AMPKα2 to AMPKα1. AMPKα2 was associated with increased mitophagy and attenuation of HF symptoms, whereas AMPKα1 expression was associated with increased HF severity. This could be related to the phosphorylation of PINK1 by AMPKα2 and the resultant activation of the mitophagy pathway. Overexpression of AMPKα2 in failing heart cardiac myocytes reversed the effects of HF and improved mitochondrial function and mitophagy. These results identify AMPKα2 as an important factor in preventing and reducing HF symptoms and raise the possibility that therapies targeted to AMPKα2 could repair cardiac myocytes during the onset of HF. 
Methods
The authors declare that all supporting data are available within the article (and in the Online Data Supplement).
Human Heart Samples
Samples from explanted hearts used in this study were obtained from 5 HF patients who had received heart transplants and 6 age-matched donors (clinical characteristics of patients are listed in Online Table  I ) at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All study participants provided informed written consent, and the study was approved by the Institutional Ethics Committee of Tongji Hospital and conducted in accordance with the principles of the Declaration of Helsinki.
The following topics and experiments are described in the Online Data Supplement: reagents, recombinant AAV9-cTNT-mediated gene transfer, TAC surgery in wild-type and AMPKα2 −/− mice, histological analysis, confocal immunofluorescence microscopy, transmission electron microscopy, mitochondrial isolation, mitochondrial respiration studies, cardiomyocyte culture and treatment, ROS measurements, AMPK activity assay, autophagy detection using the mRFP-GFP (green fluorescent protein) adenoviral vector, phos-tag assay, flow cytometry, liquid chromatography-tandem mass spectrometry analysis of PINK1-myc, fluorescence-activated cell sorting for the purification of nonmyocyte fractions, coimmunoprecipitation, and immunoblotting.
Results
Mitochondrial Dysfunction in HF Is Associated With a Switch in AMPKα Isoforms in the Heart
Emerging evidence points to the disruption of energy homeostasis and mitochondrial dysfunction as major causes of cardiac hypertrophy and progression to HF. 20, 21 Using heart tissue samples from HF patients and healthy donors, we analyzed the mitochondrial abnormalities that occurred during HF, including irregular mitochondrial arrangement, swelling, reduced density, and rates of mitophagy (Online Figure IA and IB). ROS production was higher in HF tissues than in normal heart tissues (Online Figure IA and IB) . However, mitochondrial complex I to IV protein contents (Online Figure IC and ID), mitochondrial DNA levels (Online Figure  IE) , ATP production (Online Figure IF) , and mitochondrial complex I to IV activity (Online Figure IG through IJ) were all decreased in failing heart tissues, suggesting that the mitochondrial dysfunction occurs in HF patients. Given the importance of AMPK in energy metabolism, we further examined the relationship between AMPK and mitochondrial dysfunction. Immunoblots showed an increase in the expression of AMPKα1 in the tissues of HF patients, but the expression of AMPKα2 decreased (Figure 1A and 1B; Online Figure IIA through IIC); these changes were accompanied by increases in the expression of atrial natriuretic peptide (ANP) and β-MHC (β-myosin heavy chain; Figure 1D ). An AMPKα activity assay revealed that the ratio of AMPKα2:AMPKα1 activity decreased to 30%:70% in failing hearts, whereas the ratio in healthy hearts was ≈70%:30% 22 ( Figure 1C) ; this suggests that an AMPKα isoform switch occurs during the progression of HF. In addition, the general cardiac autophagy level was decreased in failing hearts (Online Figure IID  through IIG) .
To further confirm whether mitochondrial dysfunction was associated with alterations in the activity of AMPKα isoforms in failing hearts, wild-type C57BL/6J mice were subjected to TAC and observed at multiple time points over 56 days. TAC surgery considerably increased blood velocity in the aortic arch of both wild-type and AMPKα2 −/− mice (Online Figure IIIA and IIIB) . In addition, the pressures in the aortic arch did not differ after 5 or 28 days, suggesting that TAC surgery was successful. Cardiac hypertrophy developed after 7 days, as shown by an increase in heart weight:body weight ratio ( Figure 1E and 1F) and left ventricular (LV) posterior wall thickness ( Figure 1G ; Online Figure IIIF and IIIG). A reduction in LV ejection fraction and LV fractional shortening was seen 7 days after TAC, and HF was observed after 28 days ( Figure 1H ). The Millar catheter depicted similar changes through echocardiographic analysis. Decreases in dP/dt max and dP/dt min were observed 7 days after TAC ( Figure 1I ). The P max and LV end-diastolic pressure were increased 3 days after TAC ( Figure 1I ). Interestingly, the expression levels of AMPKα1 and AMPKα2 showed an initial increase 5 days after TAC, but the expression of AMPKα2 began to decrease 14 days after TAC. Similarly, AMPKα1 and AMPKα2 activity showed an initial increase 5 days after TAC, but AMPKα2 activity showed a considerable decrease 14 days after TAC. This decrease in AMPKα2 activity was negatively associated with the expressions of ANP and β-MHC, which are markers of HF ( Figure 1J through 1L 23 During HF, the role of AMPKα2 in the activation of mitophagy is not well understood. Therefore, we first examined general autophagy in the cardiac tissue of TAC-induced mice based on the levels of Figure 1 Continued. were upregulated in the failing human heart; *P<0.05 vs non-HF patients; **P<0.01 vs non-HF patients. E, C57BL/6J mice were subjected to either sham operation (n=20) or transverse aortic constriction (TAC) and observed after 3, 5, 7, 14, 21, 28, or 56 d (n=9, 10, 12, 10, 9, 11, or 12, respectively). Gross morphologies of adult hearts in wild-type (WT) mice after TAC at different days are shown. F, Heart weight:body weight ratios of adult WT mice after TAC. *P<0.05 vs sham group. G, Representative images of echocardiograms. H, Heart rate, left ventricular ejection fraction (LVEF), LV fractional shortening (LVFS), and LV internal diameter at end systole (LVIDs) are presented. *P<0.05 vs sham group. I, Peak systolic pressure (P max ), peak instantaneous rate of left ventricular pressure increase (dP/dt max ), peak instantaneous rate of decline in left ventricular pressure increase (dP/dt min ), and LV end-diastolic pressure (LVEDP) were detected by the Millar catheter system in mouse hearts after TAC. *P<0.05 vs sham group. J, Representative immunoblots show expression levels of AMPKα1, AMPKα2, ANP, and β-MHC in mouse hearts after TAC. K, Expression levels of AMPKα1 and AMPKα2 were quantified and shown as relative protein expression after normalization to GAPDH. LC3 (light chain 3) and SQSTM1 (sequestosome-1). LC3-II levels were increased at 3, 5, and 7 days after TAC, returned to basal levels at 14 days, and showed a considerable decrease after 28 days. Moreover, in the presence of the autophagy inhibitor chloroquine, LC3-II levels showed a greater increase 5 days after TAC (Figure 2A through 2D ). SQSTM1 showed an increase from 7 days after TAC (Figure 2A and 2B). Next, autophagic flux was evaluated in primary adult mouse cardiomyocytes transduced with Ad-mRFP-GFP-LC3. 24 Both GFP/RFP double-positive autophagosomes (yellow) and RFP-positive autolysosomes (red) showed a considerable increase at 5 days in the TAC group compared with the sham group. Furthermore, chloroquine induced a considerably greater increase in the number of yellow dots at day 5 in the TAC group compared with the sham group ( Figure 2E and 2F). These results suggest that autophagic flux is increased in the early phase of TAC (5 days). In addition to general autophagy, we examined the extent of mitophagy by transmission electron microscopy in TAC-induced mice. The incorporation of mitochondria into autophagic vacuoles was found more frequently in the hearts of TAC-induced mice than in the hearts of sham mice at day 5 post-surgery, accompanied with increased LC3-II levels and decreased SQSTM1 levels ( Figure 2G through 2J); this is indicative of an increase in mitophagy after 5 days. Conversely, during the chronic phase (28 and 56 days) of TAC, mitophagy levels showed a considerable decrease, along with increased incidences of irregular mitochondrial arrangement, swelling, and reduced density ( Figure 2G and 2H). Several mitochondrial protein complex subunits (MT-ND1, MT-CYB, MT-CO2, and UQCRC2) showed a transient decrease during the early phase of TAC (5 and 7 days), but these levels returned to baseline during the chronic phase ( Figure 2K and 2L). This suggests a compensatory increase in mitophagy during the early phase of TAC, as well as suppression of mitophagy during the chronic phase of TAC. In addition, the protein most commonly associated with mitophagy, PINK1, showed a gradual decrease in both the cytosol and mitochondria during the initial 5 days after TAC. During the same period, the translocation of Parkin from the cytosol to the mitochondria was attenuated in the hearts of TAC-induced mice ( Figure 2M through 2O). Activities of PINK1, as reflected by p-Parkin S65, 25 were initially increased at 5 and 7 days after TAC and were rapidly reduced 14 days after TAC ( Figure 2M and 2O). These data suggest that cardiac mitophagy is transiently increased during the early phase but is downregulated during the chronic phase of TAC-induced HF. Furthermore, this was associated with changes in the expression levels and activities of PINK1.
AMPKα2 Protects Mice Against TAC-Induced HF by Increasing Cardiac Mitophagy Associated With PINK1-Parkin-SQSTM1 Pathway Activation
To confirm whether the reduced activity of AMPKα2 exacerbated HF via the downregulation of cardiac mitophagy, we examined the extent of mitophagy in mice after TAC through AMPKα2 gain-of-function and loss-of-function experiments. The rAAV9-cTNT-mediated overexpression of AMPKα2 protected heart tissues against chronic TAC-induced HF in mice; this was indicated by reduced heart weight:body weight ratios ( Figure 3A and 3B), attenuated lung edema (Online Figure IVA) , and increased LV ejection fraction ( Figure 3C Figure 3I and 3J). Transmission electron microscopy revealed that the incorporation of mitochondria into autophagic vacuoles was not found in the hearts of TACinduced mice at day 28, but the overexpression of AMPKα2 rescued mitophagy rates ( Figure 3I and 3K). ROS production ( Figure 3I and 3L) and cardiomyocyte apoptosis ( Figure 3I and 3M) were reduced after AMPKα2 overexpression. In addition, PINK1 was increased in the mitochondrial fraction after AMPKα2 overexpression. Parkin translocation from the cytosol to the mitochondria, as well as the subsequent recruitment of SQSTM1, was enhanced in the hearts of TAC-induced mice after AMPKα2 overexpression ( Figure 3N ). Activities of Overexpression of AMPKα2 (AMP-activated protein kinase-α2) protects mice against transverse aortic constriction (TAC)-induced heart failure (HF) associated with increasing cardiac mitophagy. C57BL/6J mice were first injected with rAAV9-cTNT-AMPKα2 in the caudal vein; rAAV9-cTNT-GFP was used as a control. After 2 weeks, infected mice were subjected to either sham operation (n=20 in rAAV9-cTNT-AMPKα2 group; n=20 in rAAV9-cTNT-GFP group) or TAC for 28 d (n=25 in rAAV9-cTNT-AMPKα2 group; n=25 in rAAV9-cTNT-GFP group). A, Gross morphology by hematoxylin and eosin (H&E) and Masson trichrome staining of (Continued ) Figure 3 Continued. adult hearts from wild-type (WT) C57BL/6J mice. Scale bars, 1.0 mm. B, Heart weight:body weight ratios of adult WT mice. *P<0.05 vs sham group; #P<0.05 vs TAC in the GFP (green fluorescent protein) group. C, Ejection fraction is shown. *P<0.05 vs sham group; #P<0.05 vs TAC in GFP group. D, Survival curve of mice in sham+rAAV9-cTNT-GFP, TAC+rAAV9-cTNT-GFP, sham+rAAV9-cTNT-AMPKα2, and TAC+ rAAV9-cTNT-AMPKα2 groups (n=15, 20, 16, or 22, respectively; P=0.0249, log-rank test). E, Myocardial ATP levels. *P<0.05 vs sham group; #P<0.05 vs TAC in GFP group. F-H, Oxygen consumption by each mitochondrial complex was calculated (n=5-7 per group). * P<0.05 vs sham group; #P<0.05 vs TAC in GFP group. I, Representative images of SQSTM1 (sequestosome-1) staining, transmission electron microscopy (TEM), dihydroethidium (DHE) staining, and the TUNEL assay in mouse heart tissues after sham operation (n=8) or 28 d after TAC (n=9). J, Number of SQSTM1-positive cardiomyocytes (CMs). K, Bar graphs indicate the number of autophagosomes containing mitochondria per total number of mitochondria from a cross-sectional assessment of the heart tissues in TEM. L, Myocardial reactive oxygen species (ROS) levels. M, Quantitative analysis of TUNEL-positive CMs. N, Top, Representative immunoblots of PINK1 (PTEN-induced putative kinase 1), Parkin, and SQSTM1 in the cytosolic fraction prepared from heart homogenates; bottom, representative immunoblots of PINK1, Parkin, and SQSTM1 in the mitochondrial fraction prepared from heart homogenates (n=4 for each group). O, Representative immunoblots and quantitative analysis of p-Parkin S65 and Parkin in the mitochondrial fraction prepared from heart homogenates (n=4 for each group) are shown. All data represent the mean±SEM from at least 4 independent experiments. VDAC indicates voltage-dependent anion channel. PINK1, as reflected by p-Parkin S65, were also increased in the hearts of TAC-induced mice after AMPKα2 overexpression ( Figure 3O ). These results suggest that the cardiac overexpression of AMPKα2 protects mice against chronic TAC-induced HF by increasing cardiac mitophagy and rescuing mitochondrial function. This role of AMPKα2 was partially mediated by the PINK1-Parkin-SQSTM1 mitophagy pathway.
In contrast, the deletion of AMPKα2 exacerbated early TAC-induced HF in mice; this was reflected by increases in heart weight:body weight ratios, increases in lung edema, and decreases in LV ejection fraction and LV fractional shortening values ( Figure 4D and 4E) . The area of cardiomyocytes with cardiac fibrosis also showed a greater increase in AMPKα2 −/− mice compared with TACinduced mice at 5 days (Online Figure IVL through IVN) . In addition, SQSTM1 accumulation was increased in cardiac tissues compared with TAC at 5 days ( Figure 4F and 4G). Transmission electron microscopy revealed a transient increase in the incorporation of mitochondria into autophagic vacuoles 5 days after TAC; this was not found in the hearts of TACinduced AMPKα2 −/− mice ( Figure 4F and 4H). ROS production showed a greater increase in AMPKα2 −/− mice compared with TAC-induced mice at 5 days ( Figure 4F and 4I) . Levels of mitochondrial PINK1 and Parkin were not observed in AMPKα2 Figure 4J ).
Moreover, AMPKα2 was able to upregulate mitochondrial biogenesis via PGC-1α (Online Figure VIB through VID) . Thus, the cardioprotective role of AMPKα2 against HF involved both mitochondrial biogenesis and mitophagy.
Overexpression of AMPKα2 Prevents the Phenylephrine-Induced Impairment of Mitophagy in Cardiomyocytes
We examined the effects of AMPKα2 on the stimulation of mitophagy in primary isolated adult mouse cardiomyocytes. Cardiomyocytes were stimulated with phenylephrine at different time points to mimic similar alterations in failing hearts in vivo. Phenylephrine stimulation for 6 hours induced the activation of AMPKα2, but no change in ANP expression was observed. Phenylephrine stimulation over a longer period (24 hours) reduced the activation of AMPKα2 and LC3-II and increased the expression of ANP (Online Figure VIIA and VIIB) . Phenylephrine stimulation for 6 and 24 hours was used to mimic early-and late-phase interventions, respectively, in subsequent experiments.
In early phenylephrine-induced HL-1 cells, intervention with the short interfering RNA (siRNA) si-AMPKα2, but not si-AMPKα1, inhibited phenylephrine-induced compensatory increases in mitophagy (Online Figure VIIIA and  VIIIB) . Moreover, 24 hours of phenylephrine stimulation markedly inhibited mitophagy in cardiomyocytes in the presence or absence of mitochondrial uncoupling proteins or carbonyl cyanide p-trichloromethoxyphenylhydrazone (CCCP; Figure 5A and 5B; Online Figure VIIIC) . Compared with the phenylephrine group, more mitochondria were found to be incorporated into autophagic vacuoles after overexpression of AMPKα2; this effect was more pronounced in the presence of CCCP ( Figure 5A and 5B). Furthermore, overexpression of AMPKα2 showed a greater increase in the ΔΨm than 24 hours of phenylephrine stimulation ( Figure 5C ; Online Figure VIIF ). To confirm that mitochondria were degraded by an autophagic process, we measured the colocalization of LC3 with mitochondria after mitochondrial depolarization using cardiomyocytes infected with adenovirus GFP-LC3. Colocalization of MitoTracker-labeled mitochondria and LC3-labeled autophagosomes was not found in phenylephrine-stimulated cardiomyocytes, but colocalization increased in the AMPKα2-overexpressed group after 8 hours of CCCP treatment (Online Figure VIIC and VIID) . Both expression levels and activities of PINK1 were increased after AMPKα2 overexpression after phenylephrine stimulation, and this was more obvious in the presence of CCCP ( Figure 5D and 5E). Examination of the mitochondrial contents by cytometry revealed that phenylephrine stimulation induced an accumulation of mitochondria in the presence of CCCP, whereas the overexpression of AMPKα2 markedly reduced the number of damaged mitochondria ( Figure 5F through 5H). Autophagic flux was then evaluated in cardiomyocytes treated with AdmRFP-GFP-LC3. Phenylephrine stimulation resulted in a decreased number of GFP/RFP double-positive autophagosomes (yellow) and RFP-positive autolysosomes (red). AMPKα2 overexpression prevented the phenylephrine-induced inhibition of autophagic flux by increasing the activity of autophagosomes and autolysosomes. Furthermore, the autophagy inhibitor bafilomycin A1 induced a much greater increase in the number of yellow dots in each group than the corresponding group without bafilomycin A1 ( Figure 5I ; Online Figure  VIIE ). These results suggest that AMPKα2 can increase autophagic flux after phenylephrine stimulation. In addition, in phenylephrine-induced cardiomyocytes, the expression levels of LC3-II, Beclin-1, and autophagy protein 5 increased, but SQSTM1 expression was reduced after the activation of AMPKα2. Overexpression of AMPKα2 also decreased ubiquitin activity in cardiomyocytes ( Figure 5J ). Hence, the overexpression of AMPKα2 prevented the phenylephrine-induced impairment of mitophagy in cardiomyocytes.
Overexpression of AMPKα2 Attenuates Phenylephrine-Induced Mitochondrial Dysfunction in Cardiomyocytes
Given that AMPKα2 prevented the phenylephrine-induced impairment of mitophagy in cardiomyocytes, we further investigated whether mitochondrial function would recover after overexpression of AMPKα2. MitoSOX red staining revealed that the overexpression of AMPKα2 prevented the late phenylephrine-induced elevation of mitochondria-derived ROS production in cardiomyocytes ( Figure 6A and 6B). Similarly, overexpression of AMPKα2 reduced total ROS levels compared with phenylephrine in cardiomyocytes ( Figure 6C and 6D). Cardiac overexpression of AMPKα2 attenuated mitochondria-derived ROS production in primary adult mouse cardiomyocytes after TAC for 28 days ( Figure 6E ). Meanwhile, activities of PINK1 were also increased after AMPKα2 overexpression ( Figure 6F ). In addition, ATP production ( Figure 6G ) and mitochondrial complex (I, II, and IV) activity recovered after AMPKα2 overexpression in phenylephrineinduced cardiomyocytes ( Figure 6H through 6K ). These data demonstrate that AMPKα2 attenuated phenylephrine-induced mitochondrial dysfunction in cardiomyocytes after increased levels of mitophagy.
AMPKα2 Interacts With PINK1 to Enhance the PINK1-Parkin-SQSTM1 Pathway
We then investigated whether AMPKα2 also enhanced cardiac mitophagy in phenylephrine-induced isolated adult mouse cardiomyocytes via the PINK1-Parkin-SQSTM1 pathway in vitro. Late phenylephrine stimulation substantially inhibited the PINK1-Parkin-SQSTM1 pathway in the presence of CCCP, accompanied with reduced AMPKα2 expression ( Figure 7A, lane 8) . On overexpression of AMPKα2, the roles of the PINK1-Parkin-SQSTM1 pathway were enhanced in the mitochondrial fractions; ubiquitin activity was also increased in isolated adult mouse cardiomyocytes ( Figure 7B, lane 8) . Moreover, the AMPKα2 overexpressionenhanced role of the PINK1-Parkin-SQSTM1 pathway was more obvious in the presence of CCCP ( Figure 7C , lane 8), indicating that AMPKα2 affects this pathway under stressful conditions. To determine how AMPKα2 upregulated the PINK1-Parkin-SQSTM1 pathway and subsequent mitophagy, we used coimmunoprecipitation assays to investigate whether AMPKα2 interacted with PINK1 in adult mouse cardiomyocytes in vitro. Endogenous PINK1 specifically interacted with AMPKα2, but not AMPKα1, in phenylephrine-induced cardiomyocytes ( Figure 7D) ; these effects were more pronounced in the presence of CCCP ( Figure 7E ). Increasing the dose of phenylephrine reduced the interactions between PINK1 and AMPKα2. Treatment with 50 μmol/L phenylephrine substantially inhibited the interactions between PINK1 and AMPKα2; this effect was more pronounced in the presence of CCCP ( Figure 7D and 7E, lane 6). In HL-1 cells, exogenous PINK1-flag and AMPKα2-myc studies also demonstrated the binding of AMPKα2 to PINK1 ( Figure 7F and 7G) . In mitochondrial fractions HL-1 cells, the overexpression of AMPKα2 prevented the phenylephrine-induced inhibition of the interactions between PINK1 and AMPKα2 ( Figure 7H and 7I, lane 8) . To determine whether PINK1 phosphorylation occurred after AMPKα2 modification, we performed PAGE that was conjugated with phos-tag. When exogenous PINK1 was subjected to PAGE with a phos-tag, a clear mobility shift was observed in PINK1. However, after 24 hours of phenylephrine stimulation, no CCCP-induced mobility shifts in PINK1 were observed, suggesting that PINK1 is phosphorylated after CCCP treatment and that 24 hours of phenylephrine treatment inhibits this phosphorylation (Online Figure IXC) . After overexpressing AMPKα2, a mobility shift in PINK1 was again observed in late phenylephrine-induced HL-1 cells after CCCP treatment ( Figure 7J, lane 4) , indicating that AMPKα2 induces the phosphorylation of PINK1. Furthermore, in CCCP-treated adult mouse cardiomyocytes, 24 hours of phenylephrine stimulation resulted in a reduced PINK1 doublet on a conventional 8% PAGE, and the upper band was not found in phos-tag-PAGE ( Figure 7K, lane  2) . The phosphorylated PINK1 band, however, was partially Figure 4 Continued. (WT) C57BL/6J mice. Scale bars, 1.0 mm. B, Heart weight:body weight ratios of adult WT mice. *P<0.05 vs sham group; #P<0.05 vs TAC in control group. C, Ejection fraction is shown. *P<0.05 vs sham group; #P<0.05 vs TAC in control group. D, Representative immunoblots of atrial natriuretic peptide (ANP), β-MHC (β-myosin heavy chain), p-AMPKα2, and AMPKα2 proteins in lysates prepared from heart homogenates (n=4 for each group). E, RT-qPCR analyses of the relative expression of nppa and myh7 from the hearts of mice exposed to the indicated conditions (n=4 for each group). F, Representative images of SQSTM1 (sequestosome-1) staining, transmission electron microscopy (TEM), and dihydroethidium (DHE) staining in heart sections from mice after sham operation (n=5) or TAC for 5 d (n=6). G, Number of SQSTM1-positive cardiomyocytes (CMs). *P<0.05 vs sham group; #P<0.05 vs TAC in control group. H, Bar graphs indicate the number of autophagosomes containing mitochondria per total number of mitochondria from a crosssectional assessment of the heart tissues in TEM. *P<0.05 vs sham group; #P<0.05 vs TAC in control group. I, Myocardial reactive oxygen species (ROS) levels. *P<0.05 vs sham group; #P<0.05 vs TAC in control group. J, Top, Representative immunoblots of PINK1 (PTENinduced putative kinase 1), Parkin, and SQSTM1 in the cytosolic fraction prepared from heart homogenates. Bottom, Representative immunoblots of PINK1, Parkin, and SQSTM1 in the mitochondrial fraction prepared from heart homogenates (n=4 for each group). K, Representative immunoblots and quantitative analysis of p-Parkin S65 and Parkin in the mitochondrial fraction prepared from heart homogenates (n=4 for each group). All data represent the mean±SEM from at least 4 independent experiments. VDAC indicates voltagedependent anion channel. rescued in an 8% phos-tag-PAGE after overexpression of AMPKα2 ( Figure 7K, lane 4) . In contrast, 6 hours of phenylephrine treatment resulted in an increased PINK1 doublet on a conventional 8% PAGE; thevupper band was slowed in phos-tag-PAGE ( Figure 7L and 7M, lane 2) . Treatment with si-AMPKα2 led to an absence of phosphorylated PINK1 in adult mouse cardiomyocytes ( Figure 7L and 7M, lane 4) , suggesting that AMPKα2 is required for the phosphorylation of PINK1. Overall, these data suggest that AMPKα2 interacts with and phosphorylates PINK1, thereby enhancing the PINK1-Parkin-SQSTM1 pathway to increase mitophagy in phenylephrine-stimulated cardiomyocytes.
AMPKα2 Activates PINK1 Mainly by Phosphorylating Ser495 to Enhance Mitophagy and Attenuate Mitochondrial Dysfunction
To understand the mechanism underlying the phosphorylation of PINK1 by AMPKα2, we investigated the AMPKα2 phosphorylation sites on PINK1. By using the phosphorylation prediction software GPS 3.0, we obtained a series of potential AMPKα2 phosphorylation sites of PINK1 and selected the 6 highest ranking sites (Ser123, Ser136, Ser199, Ser284, Ser477, and Ser495; Figure 8A ). We consequently replaced these Ser residues with Ala. Mutation of the AMPKα2 consensus sites (Ser123 and Ser199) in PINK1 did not have a substantial effect on PINK1 phosphorylation by AMPKα2 in cardiomyocytes. The Ser284Ala mutation had a slight effect on PINK1 phosphorylation. However, the Ser495Ala mutation resulted in a substantial reduction in PINK1 phosphorylation by AMPKα2 in HL-1 cells. The Ser284Ala and Ser495Ala double mutant showed no decreases in PINK1 phosphorylation by AMPKα2 in HL-1 cells (Figure 8B ), indicating that the Ser495 site has an important role in phosphorylation. In addition, antiserine levels were reduced by AMPKα2 in both Ser284Ala and Ser495Ala mutants ( Figure 8C ). To further confirm the phosphorylation of PINK1 by AMPKα2 in HL-1 cells, liquid chromatography-tandem mass spectrometry detection was performed. AMPKα2 overexpression showed a greater increase in base peaks than Ad-LacZ for PINK1 ( Figure 8D and 8E) , suggesting that PINK1 is modified by AMPKα2. Of the 10 highest ranking phosphorylated peptides by AMPKα2, PINK1 Ser495, Ser284, and Ser228 were also phosphorylated by AMPKα2. Furthermore, Ser228 was autophosphorylated by PINK1 (Online Table III ). Ser495 was evolutionarily conserved and was an optimal AMPK substrate, according to a multiple sequence alignment of PINK1 residues neighboring Ser495 in various organisms ( Figure 8F ). Thus, AMPKα2 activated PINK1 mainly by phosphorylating Ser495 in cardiomyocytes.
Next, we examined the functional role of Ser284 and Ser495 phosphorylation in PINK1 activation. The PINK1-stimulated ubiquitination of Parkin was decreased in Ser495Ala and Ser284Ala mutants; Ser495Ala showed more pronounced effects than Ser284Ala ( Figure 8G ). Under physiological conditions, PINK1 Ser284Ala did not alter mitochondrial contents, but PINK1 Ser495Ala resulted in increased mitochondrial contents in adult mouse cardiomyocytes. Under phenylephrine-induced conditions, PINK1 Ser495Ala and Ser284Ala both increased mitochondrial contents after AMPKα2 overexpression ( Figure 8H ). In addition, mitochondria-derived ROS production was increased in PINK1 Ser495Ala under physiological conditions. However, PINK1 Ser495Ala and Ser284Ala both resulted in increased mitochondria-derived ROS production in phenylephrine-induced adult mouse cardiomyocytes. PINK1 Ser495Ala induced higher levels of ROS production than Ser284Ala ( Figure 8I ). Furthermore, Ser495Ala reduced PINK1 activities (reflected by p-Parkin S65) after AMPKα2 overexpression ( Figure 8J ), accompanied by increased mitochondrial content ( Figure 8K ) and reduced mitophagy levels (Online Figure IXG) in phenylephrine-treated HL-1 cells. In contrast, Asp (phosphorylation mimic) mutation of PINK1 Ser495 promoted mitophagy (Online Figure  IXG) . Recombinant functional AMPKα2β2γ1 directly bound to and phosphorylated PINK1 at Ser495 ( Figure 8L ). In vivo, PINK1 Ser495 was also phosphorylated by overexpression of AMPKα2 after TAC, but this phosphorylation effect was abolished in AMPKα2 −/− mice ( Figure 8M and 8N ). These data suggest that overexpression of AMPKα2 mainly phosphorylates PINK1 Ser495 to remove damaged mitochondria, enhance mitophagy, and attenuate mitochondrial dysfunction in cardiomyocytes under stressful conditions.
Discussion
In this study, we show that AMPKα2 phosphorylated PINK1 to attenuate HF by improving cardiac mitophagy levels. Mechanistically, in the failing heart, the predominant AMPKα isoform switched from AMPKα2 to AMPKα1. This AMPKα isoform switch resulted in suppressed AMPKα2 activity and an impairment of mitophagy in the heart, leading to an accelerated progression to HF. However, the overexpression of AMPKα2 rescued the impairment of mitophagy by phosphorylating PINK1 at Ser495, thereby stimulating the PINK1-Parkin-SQSTM1 pathway to increase mitochondrial autophagy. The increase in cardiac mitophagy level caused the removal of damaged mitochondria and improved mitochondrial function. Our proposed model for the mechanism by which AMPKα2 mediates a protective effect against HF by increasing mitophagy is summarized in Online Figure X .
The word mitophagy is a contraction of mitochondria and autophagy and refers to the process by which cells degrade their own mitochondria. The engulfment of mitochondria by autophagosomes and the subsequent transfer to degradative lysosomes can occur during generalized macroautophagy, which may depend on effects such as nutrient deprivation. This process may also occur as a highly selective process that targets dysfunctional mitochondria. Selective mitophagy as a means of mitochondrial quality control was the current focus of our study. 26, 27 Previous studies have also revealed that autophagic or mitophagic defects are associated with an increased likelihood for laboratory animals to spontaneously develop specific cardiovascular disorders, including multiple forms of cardiomyopathy. Moreover, the pharmacological or genetic inhibition of autophagy often accelerates disease progression and worsens disease outcome in multiple animal models of cardiovascular disease. Thus, it is necessary to clarify the mechanisms underlying selective mitophagy during the progression of cardiovascular diseases, especially HF. To date, many studies have identified various molecules to be involved in selective mitophagy. For example, aside from the above-mentioned PINK1-Parkin-mediated mitophagy pathway, the partially redundant roles of BCL2 interacting protein 3 like and BCL2 interacting protein 3 may be important in the maintenance of mitochondrial homeostasis via mitophagy 28 in cardiomyocytes. In addition, the cardioprotective effects of mitophagy may be partially mediated by FUN14 domain-containing protein 1 in mammalian cells 29 and in specific models of myocardial infarction. 30 Mitochondria are the most important organelles in the regulation of energy generation. Indeed, AMPK is a potent stimulator of autophagy that responds to declining ATP levels by inhibiting mammalian target of rapamycin complex 1 and directly activating several proteins involved in the initiation of autophagy, including unc-51 like autophagy activating kinase, Beclin-1, and phosphatidylinositol 3-kinase catalytic subunit type 3. [31] [32] [33] Although a recent study has reported that AMPK mediates mitochondrial fission in response to energy stress, 19 it remains unclear whether AMPK has a role in the subsequent mitophagy process during HF.
In agreement with previous observations, we found that the failing heart showed an isoform shift that was accompanied by increases in the expression of AMPKα1 22, 34 and decreases in the expression of AMPKα2. Recent reports have determined that the ubiquitin ligase Cidea ubiquitinates the β-subunit of AMPK, leading to degradation. Atypical ubiquitination has been identified on the α-subunit and 2 of the regulatory AMPK kinases, NUAK1 (NUAK family kinase 1) and MARK4 (MAP/microtubule affinity-regulating kinase 4), which regulate AMPK activity. 35, 36 The process of ubiquitination in HF is also dysregulated. 37 Thus, we speculated that the reduced expression of AMPKα2 was associated with differential rates of degradation of the α-isoforms of AMPK during HF. Reduced AMPKα2 activity in failing hearts resulted in impaired mitophagy, leading to an acceleration of HF progression. AMPKα2 has been suggested to be the more important isoform for determining cardiac function during cardiac stress. 17 In the current study, AMPKα2 was more important than AMPKα1 in cardioprotection, especially as a regulator of mitochondrial function, which is thought to counteract cardiac remodeling. 34 Increased expression of AMPKα1 has been shown to promote myocardial activator protein-1 activation in a protein kinase C zeta-dependent manner, thereby contributing to cardiac stress signaling. 38 In conclusion, in failing hearts, the dominant AMPKα isoform switched from AMPKα2 to AMPKα1, which accelerated HF. Our data define an important relationship between AMPKα2 and PINK1 and have identified a novel mechanism showing the anti-HF effects of these proteins. Although AMPKα2 is a highly conserved sensor of mitochondrial damage across eukaryotes, PINK1 is one of the first AMPKα2 substrates to be discovered to directly control mitophagy during HF. We conclude that phosphorylation of Ser495 in PINK1 by AMPKα2 is essential for efficient mitophagy to prevent the progression of HF and provide a potential therapeutic strategy by upregulating AMPKα2. Figure 7 Continued. mitochondrial fractions were extracted for immunoprecipitation with AMPKα2-specific antibody or a control IgG, followed by probing with antibodies specific for PINK1. I, Relative binding between PINK1 and AMPKα2 in the indicated groups. *P<0.05 vs Ad-LacZ group; #P<0.05 vs PE+Ad-LacZ group. J, Endogenous PINK1 mobility was examined by Western blotting. K, Isolated mouse adult CMs were infected with ad-AMPKα2 and treated with PE (50 μmol/L, 24 h) and then with 20 μmol/L CCCP for 8 h; subsequently, they were subjected to SDS-PAGE±phos-tag and immunoblotted using an anti-PINK1 antibody. Red asterisks show phosphorylated PINK1. L, M, Isolated mouse adult CMs were infected with AMPKα2 short interfering RNA (si-AMPKα2), treated with PE (50 μmol/L, 6 h), subsequently subjected to SDS-PAGE±phos-tag and then immunoblotted using an anti-PINK1 antibody. Red asterisks show phosphorylated PINK1. All data represent the mean±SEM from at least 4 independent experiments. IB indicates immunoblotting; IP, immunoprecipitation; and VDAC, voltage-dependent anion channel. 
